Leukotriene activity modulation in asthma

Drugs

Volumn 54, Issue 3, 1997, Pages 369-384

  Spector, S L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; ZAFIRLUKAST; ZILEUTON;

AIRWAY OBSTRUCTION; ASTHMA; BRONCHOSPASM; EXTRAVASATION; HEADACHE; MUCUS SECRETION; RASH; RESPIRATORY TRACT MUCOSA; REVIEW;

EID: 0030780052     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754030-00002     Document Type: Review

References (124)

1. National Asthma Education Program. Expert Panel report: guidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute/National Institutes of Health publication no. 91-3042, 1991
2. National Heart, Lung, and Blood Institute. Global initiative for asthma. National Institutes of Health publication no. 95-3659, 1995
3. Carmichael J, Paterson IC, Diaz P, et al. Corticosteroid resistance in clinical asthma. BMJ 1981; 282: 1419-22
4. Toogood JH, Jennings B, Baskerville JC, et al. Dosing regimen of hudesonide and occurrence of oropharyngeal complications. Eur Respir J 1984; 65: 35-44
5. Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med 1995; 98: 196-208
6. Feldberg W, Kellaway CH. Liberation of histamine and formation of lysolecithin-like substances by cobra venom. J Physiol 1938; 94: 187-226
7. Samuelsson B. Leukotrienes: mediators of immediate hyper-sensitivity reactions and inflammation. Science 1983; 220: 568-75
8. Henderson WRJ. Eicosanoids and lung inflammation. Am Rev Respir Dis 1987; 135: 1176-85
9. Henderson WR. The role of leukotrienes in inflammation. Ann Intern Med 1994; 121: 684-97
10. Plaut M, Pierce JH, Watson CJ, et al. Mast cell lines produce lymphokines in response to cross-linkage of Fc epsilon RI or to calcium ionophores. Nature 1989; 339: 64-7
11. 4 synthase. Proc Natl Acad Sci USA 1992; 89: 11603-6
12. 4. J Biol Chem 1989; 264: 19469-72
13. 4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1989; 1: 584-8
14. 4 by transcellular biosynthesis. Proc Natl Acad Sci USA 1986; 83: 1349-53
15. Goldman DW, Goetzl EJ. Heterogeneity of human polymorphonuclear leukocyte receptors for leukotriene B4: identification of a subset of high-affinity receptors that transduce the chemotactic response. J Exp Med 1984; 159: 1027-41
16. O'Donnell M, Welton A. Comparison of the pulmonary pharmacology of leukotrienes and PAF: effects of their antagonists. In: Lewis AJ, Doherty NS, Ackeman NR, editors. Therapeutic approaches to inflammatory diseases. New York: Elsevier, 1989: 169-93
17. 4 in the guinea pig lung. Biochem Biophys Res Commun 1983; 116: 1136-43
18. 4 induced contraction in guinea pig pulmonary parenchymal strips. J Pharmacol Exper Ther 1987; 243: 424-9
19. 4. J Pharmacol Exp Ther 1986; 237: 558-62
20. Drazen JM. Comparative contractile responses to sulfidopeptide leukotrienes in normal and asthmatic human subjects. Ann NY Acad Sci 1988; 524: 289-97
21. Spector SL, Nicklas RA, Eds. Practice parameters for the diagnosis and treatment of asthma. J Allergy Clin Immunol 1995; 96 Suppl.: 707-870
22. Rinkema LE, Bemis KG, Fleish JH. Production and antagonism of cutaneous vascular permeability in the guinea pig in response to histamine, leukotrienes, and A23187. J Pharmacol Exp Ther 1984; 230: 550-7
23. 4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1982; 126: 449-51
24. 4 effects on in vitro ciliary beat frequency of human upper respiratory cilia. Eur Arch Otorhinolaryngol 1994; 251: 325-8
25. Dahlen S-E, Hedqvist P, Hammarstrom S, et al. Leukotrienes are potent constrictors of human bronchi. Nature 1980; 288: 484-6
26. Bousquet J, Chanez P, Laqcoste J, et al. Eosinophilic inflammation in asthma. N Engl J Med 1990; 323: 1033-9
27. 4) in human skin. J Invest Dermatol 1983; 80: 115-9
28. Laitinen LA, Laitinen A, Widdicombe J. Effects of inflammatory and other mediators on airway vascular beds. Am Rev Respir Dis 1987; 135: 567-70
29. Williams TJ, Piper PJ. The action of chemically pure SRS-A on the microcirculation in vitro. Prostaglandins 1980; 19: 779-86
30. 4 on glycoprotein and lysozyme secretion by human bronchial mucosa. Prostaglandins 1983; 25: 155-70
31. 4 and histamine in exogenous asthma. BMJ 1985; 290: 1468-71
32. 4 in humans. Am Rev Respir Dis 1985; 131: 368-72
33. 4 in normal and asthmatic subjects. Am Rev Respir Dis 1987; 135: 333-7
34. 4 in the human lung: recruitment of neutrophils into the alveolar spaces without a change in protein permeability. J Clin Invest 1989; 84: 1609-19
35. 4 is a potent and stereospecific stimulator of neutrophil chemotaxis and adherence. Blood 1981; 58: 658-63
36. Erger RA, Casale TB. Comparative studies indicate that platelet-activating factor is a relatively weak eosinophilotactic mediator. Am J Respir Cell Mol Biol 1995; 12: 65-70
37. Goetzl EJ, Derian CK, Owens CJ, et al. Modulation of the PMN leukocyte component of hypersensitivity reactions by lipoxygenase products or arachidonic acid. In: Hadden J, Chedid L, Mullen P, et al., editors. Advances in immunopharmacology. Oxford: Pergamon Press, 1981: 343-53
38. 4. Br Med Bull 1983; 39: 249-54
39. 2 [abstract]. Proc Br Pharmacol Soc 1988 Jan 6-8; 15: 667
40. 4 effects on human eosinophil and neutrophil molility in vitro. J Leukoc Biol 1994; 55: 183-91
41. Krauss AH, Woodward DP. Polymorphonuclear leukocyte infiltration into the subretinal choroid and optic nerve in response to leukotrienes. Invest Ophthalmol Vis Sci 1993; 34: 3679-86
42. Krauss AH, Nieves AL, Spada CS, et al. Determination of leukotriene effects on human neutrophil chemotaxis in vitro by differential assessment of cell motility and polarity. J Leukoc Biol 1994; 55: 201-8
43. 4 in human lymphocyte cultures. Prostaglandins Leukot Med 1986; 23: 207-10
44. 4 and platelet-activating factor on airway reactivity in normal subjects. Am Rev Respir Dis 1990; 141: 993-7
45. 4 on the airway responsiveness to histamine in subjects with asthma and normal subjects. J Allergy Clin Immunol 1988; 82: 654-60
46. 4 antagonism in a primate model of asthma. J Clin Invest 1996; 97: 381-7
47. 4 receptor antagonist ICI 204,219. Am Rev Respir Dis 1993; 147: 215-7
48. 4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1989; 1: 584-8
49. 4 levels after allergen and exercise challenge in bronchial asthma. Am Rev Respir Dis 1991; 144: 1411-3
50. 4 and histamine in asthmatics. Am Rev Respir Dis 1992; 146: 96-103
51. 4 in blood of asthmatic children. Biochem Biopys Res Commun 1985; 130: 486-92
52. 4 during wheezing attacks in asthmatic patients. Int Arch Allergy Appl Immunol 1987; 84: 149-55
53. 4 in bronchoalveolar lavage in bronchial asthma and other diseases. J Allergy Clin Immunol 1989; 84: 19-26
54. Lam S, Chan H, LeRiche JC, et al. Release of leukotrienes in patients with bronchial asthma. J Allergy Clin Immunol 1988; 81: 711-7
55. 4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis 1990; 142: 112-9
56. Broide DH, Eisman S, Ramdel JW, et al. Airway levels of mast cell-derived mediators in exercise-induced asthma. Am Rev Respir Dis 1990; 141: 563-8
57. Drazen JM. Pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in the management of asthma. Pharmacotherapy 1997; 17: 22S-30S
58. Busse WW, Gaddy JN. The role of leukotriene antagonists and inhibitors in the treatment of airway disease. Am Rev Respir Dis 1991; 143: S103-7
59. Hui KP. Leukotriene antagonists and synthesis inhibitors: just about to prove their worth? Curr Med Literature 1992; 6: 87-92
60. Ford-Hutchinson A. Leukotriene antagonists and inhibitors as modulators of IgE-mediated reactions. Springer Semin Immunopathol 1993; 15: 37-50
61. McMillan RM. Inhibitors of leukotriene synthesis and actions: asthma drugs of the near future? Intern Acad Biomed Drug Res 1993; 6: 71-85
62. Chanarin N, Johnston SL. Leukotrienes as a target in asthma therapy. Drugs 1994; 47: 12-24
63. Diamant Z, Lammers J-WJ, Sterk PJ. Leukotriene receptor antagonists and biosynthesis inhibitors in asthma. Clin Immunother 1994; 2: 220-32
64. Spector SL. Leukotriene inhibitors and antagonists in asthma. Ann Allergy Asthma Immunol 1995; 75: 463-70
65. Spector SL. Management of asthma with zafirlukast: clinical experience and tolerability profile. Drugs 1996; 52: 36-46
66. Drazen JM. Leukotrienes. In: Busse WW, Holgate ST, editors. Asthma and rhinitis. Oxford: Blackwell Scientific, 1994
67. 4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI-204,219. Clin Pharmacol Ther 1993; 54: 430-6
68. 4-induced bronchoconstriction in normal volunteers. Eur J Clin Pharmacol 1994; 47: 227-30
69. 4 receptor antagonism in the airways of asthmatics [abstract]. Am J Respir Crit Care Med 1994; 149: A465
70. Nakagawa T, Mizushima Y, Ishii A, et al. Effect of a leukotriene antagonist on experimental and clinical bronchial asthma. Adv Prostaglandin Thromboxane Leukot Res 1990; 21: 465-8
71. Fischer AR, McFadden CA, Frantz R, et al. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects. Am J Respir Crit Care Med 1995; 152: 1203-7
72. Taylor IK, O'Shaughnessy KM, Fuller RW, et al. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airways hyper-reactivity in atopic subjects. Lancet 1991; 337: 690-4
73. Nathan RA, Glass M, Minkwitz MC. Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma. Chest 1994; 105: 483-8
74. Taniguchi Y, Gamura G, Honma M, et al. The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. J Allergy Clin Immunol 1993; 92: 507-12
75. 4) receptor antagonist, on ascaris antigen-induced early and late phase airway responses in conscious squirrel monkeys [abstract]. Am J Respir Crit Care Med 1994; 149: A533
76. 4 receptor antagonist. Can J Physiol Pharmacol 1995; 73: 191-201
77. 4 antagonist L648,051. Allergy 1992; 46: 604-9
78. Kelly LJ, Undem BJ, Adams GKI. Antigen-induced contraction of guinea pig isolated pulmonary arteries and lung parenchyma. J Appl Physiol 1993; 74: 1563-9
79. Dahlen S-E, Dahlen B, Ihre E, et al. The leukotriene biosynthesis inhibitor Bay × 1005 is a potent inhibitor of allergen-induced airway obstruction and leukotriene formation in man [abstract]. Am Rev Respir Dis 1993; 142: A837
80. O'Byrne PM, Watson RM, Strong HA, et al. The effect of treatment with a 5-lipoxygenase inhibitor. Bay × 1005 on allergen-induced asthmatic responses in human subjects [abstract]. Am J Respir Crit Care Med 1994; 149: A532
81. Malo PE, Bell RL, Shaughnessy TK, et al. The 5-lipoxygenase inhibitory activity of zileuton in in vitro and in vivo models of antigen-induced airway anaphylaxis. Pulmon Pharmacol 1994; 7: 73-9
82. Juniper EF, Kline PA, Vanzielehgem MA, et al. Effect of long-term treatment with an inhaled corticosteroid on airway hyperresponsiveness and clinical asthma in non-steroid dependent asthmatics. Am Rev Respir Dis 1990; 142: 832-6
83. Rosenthal R, Lavins BJ, Hanby LA. Effect of treatment with zafirlukast (Accolate™) on bronchial hyperresponsiveness in patients with mild-to-moderate asthma [abstract]. J Allergy Clin Immunol 1996; 97: 250
84. Fujimura M, Sakamoto S, Matsuda T. Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma. Respir Med 1993; 87: 133-8
85. Taki F, Suzuki R, Torii K, et al. Reduction of the severity of bronchial hyperresponsiveness by the novel leukotriene antagonist, 4-oxo-8-[4-(4-phenylbutoxy) benzoylamineo]-2-(tetrazol-5-yl)-4H-1-benzopyran hemihydrate. Arzneimittel Forschung 1994; 44 (3): 330-3
86. 4 in guinea pigs. Clin Exp Allergy 1994; 24: 960-8
87. Howell RE, Sickels BD, Woeppel SL, et al. Leukotrienes mediate antigen-induced airway hyper-reactivity in guinea pigs. J Pharmacol Exp Ther 1994; 268: 353-8
88. Nagai H, Takeda H, Uno T, et al. Effect of a novel leukotriene synthesis inhibitor, BAY × 1005, on the antigen-and LPS-induced airway hyperresponsiveness in guinea pigs. Prostaglandins 1996; 51: 139-48
89. Ishida K, Thomson RJ, Schellenberg RR. Role of leukotrienes in airway hyperresponsiveness in guinea-pigs. Br J Pharmacol 1993; 108: 700-4
90. 4 receptor antagonist, SC-53228, on ozone-induced airway hyperresponsiveness and inflammation in dogs. Am J Respir Crit Care Med 1995; 152: 1443-8
91. Anderson SD. Issues in exercise-induced asthma. J Allergy Clin Immunol 1985; 76: 763-72
92. 4-receptor antagonist. N Engl J Med 1991; 323: 1736-9
93. 4 antagonist. Am Rev Respir Dis 1992; 145: 746-9
94. 4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis 1993; 147: 1413-8
95. Reiss T. MK-0476, a potent and specific leukotriene (LT) D-4 receptor antagonist exhibits a dose response in the inhibition of exercise induced bronchoconstriction at the end of a once daily dosing interval [abstract]. J Invest Med 1995; 43: 275A
96. Robuschi M, Riva E, Fuccella WM, et al. Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK&F 104,353). A double-blind study versus disodium cromoglycate and placebo. Am Rev Respir Dis 1992; 145: 1285-8
97. 4 antagonist) on exercise-induced bronchospasm [abstract]. Eur Respir J 1996; 9: 272S
98. Mann JS, Robinson C, Sheridan AQ, et al. Effect of inhaled piriprost (U-60,257) a novel leukotriene inhibitor, on allergen and exercise induced bronchoconstriction in asthma. Thorax 1986; 41: 746-52
99. Meltzer SS, Hasday JD, Cohn J, et al. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med 1996; 153: 931-5
100. Israel E, Dermarkanan R, Rosenbeg M, et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 1990; 323: 1769-70
101. Fischer AR, McFadden CA, Frantz R, et al. Chronic inhibition of 5-lipoxygenase decreases airway reactivity to cold, dry air independent of the acute inhibition of 5-lipoxygenase [abstract]. Am J Respir Crit Care Med 1994; 149: A1056
102. Fischer AR, Drazen JM, Roth M, et al. The effect of a leukotriene synthesis inhibitor, Bay × 1005, on bronchoconstriction induced by cold, dry air hyperventilation in asthmatics [abstract]. Am J Respir Crit Care Med 1994; 149: A1056
103. Israel E, Juniper EF, Callaghan JT, et al. Effect of a leukotriene antagonist, LY 171883, on cold air-induced bronchoconstriction in asthmatics. Am Rev Respir Dis 1989; 140: 1348-53
104. 4-receptor antagonist, ICI 204,219, on cold-air-induced bronchoconstriction in patients with asthma [abstract]. J Allergy Clin Immunol 1994; 93: 295
105. Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SKF 104,353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991; 144: 957-8
106. Yamamoto H, Nagata M, Kuramitsu K, et al. Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ONO-1078. Am J Respir Crit Care Med 1994; 150: 254-7
107. Dahlen B, Kumlin M, Margolskee JJ, et al. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. Eur Respir J 1993; 6: 1018-26
108. Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148: 1447-51
109. Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1991; 337: 1062-3
110. Wisniewski PL, Busse WW, Meltzer SS, et al. Bronchodilatory effects of Bay × 7195, a selective leukotriene receptor antagonist [abstract]. J Allergy Clin Immunol 1995; 95: 639
111. Spector SL, Glass M, Minkwitz M, et al. The effect of six weeks of therapy with oral doses of ICI 204,219 in asthmatics [abstract]. Am Rev Respir Dis 1992; 145: A16
112. 4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994; 150: 618-23
113. 4 receptor antagonist, in patients with chronic asthma [abstract]. J Allergy Clin Immunol 1991; 87: 309
114. 4) antagonist (MK-0476) in patients with asthma [abstract]. Am J Respir Crit Care Med 1994; 149: A216
115. 4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996; 98: 528-34
116. 1 in patients with asthma: results of a 12-week, multicenter study vs. nedocromil [abstract]. Am J Respir Crit Care Med 1997; 155: A665
117. Israel B, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderale asthma. Ann Intern Med 1993; 119: 1059-66
118. Israel E, Cohn J, Dube L, et al. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. JAMA 1996; 275: 931-6
119. Wenzel SE, Trudeau JB, Kaminsky DA, et al. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med 1995; 152: 897-905
120. Chapman KR, Friedman BS, Shingo S, et al. The efficacy of an oral inhibitor of leukotriene synthesis. MK-0591, in asthmatics treated with inhaled steroids [abstract]. Am J Respir Crit Care Med 1994; 149: A215
121. Chen X-S, Sheller JR, Johnson EN, et al. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 1994; 372: 179-82
122. Israel E, Rubin P, Kemp J, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993; 119: 1059-66
123. Abbott Laboratories, Inc. Package insert for Zyflo™ (zileuton). December 1996
124. Munoz NM, Douglas I, Mayer D, et al. Eosinophil chemotaxis inhibited by 5-lipoxygenase blockade and leukotriene receptor antagonism. Am J Respir Crit Care Med 1997; 155: 1398-403